In this episode, host Shikha Jain, MD, speaks with Michel van Harten, MD, about creating better information systems for physicians and patients, how shared decision-making can improve drug development and more. • Welcome to another exciting episode of Oncology Overdrive 0:14 • About van Harten 0:20 • The interview 1:00 • What was your journey to becoming a physician and beyond to where you are now? 1:24 • How did you learn the necessary skills to be an exceptional leader in this space? 2:51 • How many years were you a practicing physician for? 3:53 • What does myTomorrows do, and what drew you to this type of work? 4:54 • Where is this service available? 7:19 • Jain and van Harten on the challenges patients face surrounding eligibility for clinical trials. 8:36 • Where do you see this going down the line? 10:05 • Has your company looked into how to these services can impact diversifying clinical trial enrollment? 12:04 • What are some challenges your company has faced? 13:50 • How quickly do you think growth will accelerate in this space? 15:26 • How will this work and resource have major impacts on drug development in a more accelerated way than in the past? 16:11 • From the patient-facing side, have you faced any challenges concerning patients’ willingness to be enrolled in clinical trials? 18:22 • What is next for you, and where do you see yourself in twenty years? 19:13 • Do you have any concerns about AI in health care? […] What should we be aware of when utilizing AI in this space? 19:45 • Jain and van Harten on the challenges and setbacks that come from outdated and inaccurate clinical trial databases. 21:35 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:50 • How to contact van Harten 24:28 • Thanks for listening 25:17 Michel van Harten, MD, is the CEO of myTomorrows.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Michel van Harten can be reached via email michel.vanharten@mytomorrows.com.

Disclosures: Jain and van Harten report no relevant financial disclosures.

Enhancing Clinical Trial Enrollment with Michel van Harten, MD